Decreased tumor surveillance after adoptive T-cell therapy

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7467-7476

  Matter, Matthias ^a,b   Pavelic, Viktor ^a   Pinschewer, Daniel D ^b   Mumprecht, Sabine ^a   Eschli, Bruno ^b   Giroglou, Tsanan ^c   Von Laer, Dorothee ^c   Ochsenbein, Adrian F ^a,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Georg Speyer Haus   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; EPITOPE; GLYCOPROTEIN GP 33; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; FIBROSARCOMA; HUMAN; HUMAN CELL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; ANTIGEN-PRESENTING CELLS; CHROMIUM; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FIBROSARCOMA; FLOW CYTOMETRY; GLYCOPROTEINS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NUCLEOPROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

EID: 34547628692     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4372     Document Type: Article

References (48)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
2. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73.
3. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
4. Figlin RA, Thompson, JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17:2521-9.
5. Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002;20:1075-86.
6. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
7. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
8. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8" T cells. J Exp Med 2003;198:569-80.
9. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-30.
10. Burnet FM. Cancer: a biological approach. Br Med J 1957;1:779-86.
11. Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
12. Pardoll D. T cells and tumours. Nature 2001;411:1010-2.
13. Kündig TM, Bachmann MF, DiPaolo C, et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995;268:1343-7.
14. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals, and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
15. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
16. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a peripheral solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999;96:2233-8.
17. Ochsenbein AF. Immunological ignorance of solid tumors. Springer Semin Immunopathol 2005;27:19-35.
18. + T cells to cause immunopathology. J Exp Med 1998;187:763-74.
19. Pircher H, Bürki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989;342:559-61.
20. Chen J, Trounstine M, Alt FW, et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 1993;5:647-56.
21. Prévost-Blondel A, Zimmermann C, Stemmer C, Klumburg P, Rosenthal FM, Pircher H. Tumor-infiltration lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998;161:2187-94.
22. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
23. -/-) mutant mice. J Exp Med 1997;185:2157-70.
24. Seiler P, Brundler MA, Zimmermann C, et al. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J Exp Med 1998;187:649-54.
25. Hangartner L, Zellweger RM, Giobbi M, et al. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med 2006;203:2033-42.
26. Beyer WR, Miletic H, Ostertag W, von Laer D. Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference. J Virol 2001;75:1061-4.
27. van der Most RG, Murali-Krishna K, Whitton JL, et al. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology 1998;240:158-67.
28. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol 2005;17:195-201.
29. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005;102:9571-6.
30. + T cells. J Clin Invest 2005;115:1616-26.
31. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-9.
32. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2005;54:187-207.
33. Sturmhoefel K, Lee K, Gray GS, et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res 1999;59:4964-72.
34. Wolpert EZ, Grufman P, Sandberg JK, Tegnesjo A, Karre K. Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J Immunol 1998;161:4499-505.
35. + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000;164:3095-101.
36. Kedl RM, Schaefer BC, Kappler JW, Marrack P. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 2002;3:27-32.
37. Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition, and T cell affinity maturation. Curr Opin Immunol 2003;15:120-7.
38. Ludewig B, Bonilla WV, Dumrese T, Odermatt B, Zinkernagel RM, Hengartner H. Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur J Immunol 2001;31:1772-9.
39. + T cells in vivo. Proc Natl Acad Sci U S A 2006;103:147-52.
40. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627-30.
41. Siegel CT, Schreiber K, Meredith SC, et al. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 2000;191:1945-56.
42. + T cell adoptive immunotherapy. Immunity 2000;13:265-76.
43. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999;59:1071-9.
44. Cordaro TA, de Visser KE, Tirion FH, et al. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Eur J Immunol 2000;30:1297-307.
45. Blohm U, Potthoff D, van der Kogel AJ, Pircher H. Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol 2006;36:468-77.
46. Wick M, Dubey P, Koeppen H, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997;186:229-38.
47. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005;437:141-6.
48. Matsui K, O'Mara LA, Allen PM. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol 2003;15:797-805.